Eli Lilly downgrades earnings per share and revenue expectations

In its latest financial report, the US-based pharmaceutical company’s expectations for full-year 2022 earnings per share and revenues have dropped. (Updated)

Photo: Mike Blake/Reuters/Ritzau Scanpix

On Tuesday, US-based Eli Lilly publicized its third-quarter report, revealing downgrades for both full-year earnings per share (EPS) and revenues.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs